Aura Biosciences
AURA
94 hedge funds and large institutions have $232M invested in Aura Biosciences in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 14 closing their positions.
0.37% more ownership
Funds ownership: 78.98% → 79.35% (+0.37%)
0% more funds holding
Funds holding: 94 → 94 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
5% less call options, than puts
Call options by funds: $36K | Put options by funds: $38K
29% less capital invested
Capital invested by funds: $324M → $232M (-$92.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$20.7M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$5.91M |
| 3 |
ACA
Acorn Capital Advisors
New York
|
+$4.47M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$3.69M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$33.5M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$3.21M |
| 3 |
JP Morgan Chase
New York
|
-$516K |
| 4 |
Morgan Stanley
New York
|
-$481K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$281K |
AURA Hedge Fund Activity: Q1 2025 in Review
94 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2025, worth a combined $232M — down 29% from $324M a quarter earlier.
Fund positioning in AURA was balanced in Q1 2025: 14 funds opened new positions, 14 closed out, 30 added to existing stakes and 30 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $20.7M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $33.5M sold.
- 94 institutional investors held Aura Biosciences (AURA) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $232M of Aura Biosciences stock for Q1 2025, down 29% quarter-over-quarter.
- 14 funds opened new Aura Biosciences positions in Q1 2025 and 14 closed out, a net change of 0 holders.
- The largest Aura Biosciences buyer in Q1 2025 was Suvretta Capital Management, an estimated $20.7M added.
- The largest Aura Biosciences seller in Q1 2025 was Eventide Asset Management, an estimated $33.5M sold.
Based on aggregated 13F filings for Q1 2025.